120 related articles for article (PubMed ID: 29355526)
1. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome.
Bosc E; Nastri J; Lefort V; Valli M; Contiguiba F; Pioli R; Furlan M; Bolzani VDS; El Amri C; Reboud-Ravaux M
Biochem Biophys Res Commun; 2018 Feb; 496(3):961-966. PubMed ID: 29355526
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.
Adams DJ; Dai M; Pellegrino G; Wagner BK; Stern AM; Shamji AF; Schreiber SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15115-20. PubMed ID: 22949699
[TBL] [Abstract][Full Text] [Related]
3. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M
J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
[TBL] [Abstract][Full Text] [Related]
5. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies.
Bandoh N; Ogino T; Cho HS; Hur SY; Shen J; Wang X; Kato S; Miyokawa N; Harabuchi Y; Ferrone S
Tissue Antigens; 2005 Sep; 66(3):185-94. PubMed ID: 16101829
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.
Zou Y; Yan C; Zhang H; Xu J; Zhang D; Huang Z; Zhang Y
Eur J Med Chem; 2017 Sep; 138():313-319. PubMed ID: 28686911
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
9. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
[TBL] [Abstract][Full Text] [Related]
10. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Kasam V; Lee NR; Kim KB; Zhan CG
Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
[TBL] [Abstract][Full Text] [Related]
12. Immunoproteasome in Macaca fascicularis: no age-dependent modification of abundance and activity in the brain and insight into an in silico structural model.
Bellavista E; Mishto M; Santoro A; Bertoni-Freddari C; Sessions RB; Franceschi C
Rejuvenation Res; 2008 Feb; 11(1):73-82. PubMed ID: 17985946
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation.
Sun AL; Mu WW; Li YM; Sun YL; Li PX; Liu RM; Yang J; Liu GY
Molecules; 2021 May; 26(11):. PubMed ID: 34071298
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insights on petrosaspongiolide M inhibitory effects on immunoproteasome and autophagy.
Monti MC; Margarucci L; Riccio R; Bonfili L; Mozzicafreddo M; Eleuteri AM; Casapullo A
Biochim Biophys Acta; 2014 Apr; 1844(4):713-21. PubMed ID: 24530967
[TBL] [Abstract][Full Text] [Related]
16. Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
Liu X; Wang Y; Zhang X; Gao Z; Zhang S; Shi P; Zhang X; Song L; Hendrickson H; Zhou D; Zheng G
Bioorg Med Chem; 2018 Aug; 26(14):3925-3938. PubMed ID: 29925484
[TBL] [Abstract][Full Text] [Related]
17. Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation.
Yan WJ; Wang Q; Yuan CH; Wang F; Ji Y; Dai F; Jin XL; Zhou B
Free Radic Biol Med; 2016 Aug; 97():109-123. PubMed ID: 27233942
[TBL] [Abstract][Full Text] [Related]
18. Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines.
Lad NP; Kulkarni S; Sharma R; Mascarenhas M; Kulkarni MR; Pandit SS
Eur J Med Chem; 2017 Jan; 126():870-878. PubMed ID: 27987486
[TBL] [Abstract][Full Text] [Related]
19. The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
Zerfas BL; Maresh ME; Trader DJ
J Med Chem; 2020 Mar; 63(5):1841-1858. PubMed ID: 31670954
[TBL] [Abstract][Full Text] [Related]
20. Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS.
Dechavanne V; Vilbois F; Glez L; Antonsson B
Protein Expr Purif; 2013 Feb; 87(2):100-10. PubMed ID: 23147206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
